Plasma and lipoprotein cholesterol and triglycerides, and plasma apolipoproteins AI, All and B were compared in patients with chronic airflow limitation, and normal controls matched for body mass index. The controls were non-smokers, and free from respiratory disease.
Introduction
A low incidence of myocardial infarction has been reported in patients with chronic airflow limitation (CAL)1. However, many such patients are frequently underweight, often markedly so, which might account, at least in part for the observation. Lipid studies too have not taken account of the possible influence of body weight, though other effects, on high-density lipoprotein cholesterol in particular, have implied that a change towards a less atherogenic pattern takes place, for instance in asthma2. To our knowledge, detailed apolipoprotein assays have not been done in CAL patients. In particular, levels of apolipoproteins (apo) AI and All, which are the predominant proteins in high-density lipoproteins (HDL), and apo B, the major protein of low-density lipoprotein (LDL) have not been reported.
In the present study we have measured plasma and lipoprotein lipids and apolipoproteins AI, All and B in a group of patients with CAL and compared them with non-smoking, respiratory disease-free controls, matched for body mass index.
Methods Patients
A group of 18 men with CAL of at least 5 years duration, and mean age 54.2 years (range 40-66) was studied. All but six patients were ex-smokers or had never smoked. Mean 
Laboratory methods
Fasting blood samples from both patients and controls were taken into EDTA. HDL was isolated after precipitation of very-low and low-density lipoproteins (VLDL and LDL, respectively) by sodium phosphotungstate/MgCl24. VLDL and HDL subfractions (HIDL2 and HDL3) were isolated in the Beckman Airfuge, the latter following adjustment of density to 1.125 g/ml5. Cholesterol and triglycerides were measured in plasma, VLDL and HDL, and cholesterol only in HDL3 by standard enzymatic methods (Boehringer Mannheim: Cat nos. 236691, 644200). LDL lipids and HDL2 cholesterol were obtained by subtraction.
Apo AI, All and B concentrations were measured by immunonephelometry6,7'8 using antibodies raised in sheep.
Statistical methods
In order to gain statistical efficiency, approximately 3 control subjects were matched with each patient9.
The means ofthe determined values were compared using one-way analysis of variance and Student's t-test. Changes which achieved statistical significance did so using both tests.
Results
Plasma and lipoprotein lipids and apolipoproteins (mean±s.d.) of the patients and control subjects areshown in Table 1 . HDL and HDL2 cholesterol were significantly raised in the patients with CAL (P=0.013 and 0.012, respectively) whilst the HDL triglycerides were significantly reduced (P=0.004). All 
Discussion
The present findings confirm those of Tisi et al.10 of a raised HDL cholesterol in patients with CAL matched for body weight with non-smoking control subjects, and adds the observation that HDL2 which is thought to exert a particular protective role against the development of ischaemic heart disease" is also elevated. The raised level of apo AI, the principal protein of HDL, adds support to this observation. Our other findings of lower HDL triglyceride and unchanged apo All in the CAL patients suggest that the HDL particle may be qualitatively different from normal. Tisi et al. suggested that the increased work of breathing may be responsible for the raised level of HDL in their patients, but the effect of drugs may also be important. Thus the I32 agonist terbutaline, when given to a group of normal males for 2 weeks, has been shown to raise the level ofHDL cholesterol'2. Similarly, Chazan et al.'3 found that oral salbutamol in a dose of 8 mg twice daily given to 30 patients with severe airways obstruction was associated with a significant rise in HDL cholesterol levels. However, Lehtonen et al.'4 reported the use of a lower dose of salbutamol of 2 mg 3 times daily for 3 months, in 13 asthmatic patients (including 10 females). They found no change in HDL cholesterol levels. This difference may be dose-related.
Recent work by Kruszynska et al. 15 has also shown a rise in HDL and total cholesterol in a group of normal young volunteers on high dose inhaled steroids. The presence of 6 smokers in our patient group, would mitigate against a change in the HDL cholesterol levels, since smoking causes a tendency to lower HDL levels'6.
Our results do not allow us to differentiate between the possible effects of beta agonist or steroid therapy, and the increased exercise load in the patients. A raised level of HDL cholesterol and apolipoprotein AI may account for the low incidence of myocardial infarction in patients with CAL and we suggest that longer term studies of beta agonist therapy and lipoprotein levels should be undertaken.
